Involvement of transcription factor activator protein-2α in doxazosin-induced HeLa cell apoptosis

Acta Pharmacologica Sinica

Volumn 29, Issue 4, 2008, Pages 465-472

  Gan, Lu ^a   Zhu, Dong Xing ^a   Yang, Li Ping ^a   Liu, Ru Shi ^a   Yan, Feng ^a   Zhang, Jian ^a  

^a HUNAN NORMAL UNIVERSITY   (China)

Author keywords

1 adrenergic inhibitor; Activator protein 2 ; Apoptosis; Caspases; Cervical cancer; Doxazosin; HeLa cells; Transcription factors

Indexed keywords

CASPASE 3; DOXAZOSIN; TRANSCRIPTION FACTOR ACTIVATOR PROTEIN 2 ALPHA; TRANSCRIPTION FACTOR AP 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE RESPONSE; FLOW CYTOMETRY; HELA CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ADRENERGIC ALPHA-ANTAGONISTS; APOPTOSIS; BISBENZIMIDAZOLE; CASPASE 3; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXAZOSIN; FLUORESCENT DYES; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; TIME FACTORS; TRANSCRIPTION FACTOR AP-2;

EID: 41549168318     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00780.x     Document Type: Article

References (31)

1. Black HR. Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. J Cardiovasc Pharmacol 2003 41: 866 9.
2. Pool JL. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J 1991 121: 251 9.
3. Lowe F. α-1-Adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1999 2: 110 9.
4. Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, et al. Effect of α1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 2007 178: 2176 80.
5. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by α 1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000 60: 4550 5.
6. Kyprianou N, Chon J, Benning CM. Effects of α (1)-adrenoceptor (α(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. Prostate 2000 9 (Suppl): 42 6.
7. Benning CM, Kyprianou N. Quinazoline-derived α 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an α1-adrenoceptor- independent action. Cancer Res 2002 62: 597 602.
8. Tahmatzopoulos A, Sheng S, Kyprianou N. Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Oncogene 2005 24: 5375 83.
9. Keledjian K, Kyprianou N. Anoikis induction by quinazoline-based α1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. J Urol 2003 169: 1150 6.
10. Partin JV, Anglin IE, Kyprianou N. Quinazoline-based α1- adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-β signalling and IKBα induction. Br J Cancer 2003 88: 1615 21.
11. Walden PD, Globina Y, Nieder A. Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase. Urol Res 2004 32: 261 5.
12. Garrison JB, Kyprianou N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res 2006 66: 464 72.
13. Shaw YJ, Yang YT, Garrison JB, Kyprianou N, Chen CS. Pharmacological exploitation of the α1-adrenoceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. J Med Chem 2004 47: 4453 62.
14. Arencibia JM, Del Rio M, Bonnin A, Lopes R, Lemoine NR, Lopez-Barahona M. Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation. Int J Oncol 2005 27: 1617 23.
15. Fernando MA, Heaney AP. α1-Adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol 2005 19: 3085 96.
16. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. Cmaj 2001 164: 1017 25.
17. Zhang J, Hagopian-Donaldson S, Serbedzija G, Elsemore J, Plehn-Dujowich D, McMahon AP, et al. Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. Nature 1996 381: 238 41.
18. Holzschuh J, Barrallo-Gimeno A, Ettl AK, Durr K, Knapik EW, Driever W. Noradrenergic neurons in the zebrafish hindbrain are induced by retinoic acid and require tfap2a for expression of the neurotransmitter phenotype. Development 2003 130: 5741 54.
19. Knight RD, Javidan Y, Zhang T, Nelson S, Schilling TF. AP2-dependent signals from the ectoderm regulate craniofacial development in the zebrafish embryo. Development 2005 132: 3127 38.
20. Turner BC, Zhang J, Gumbs AA, Maher MG, Kaplan L, Carter D, et al. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res 1998 58: 5466 72.
21. Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, et al. Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer 2004 40: 1485 95.
22. Odegaard E, Staff AC, Kaern J, Florenes VA, Kopolovic J, Trope CG, et al. The AP-2γ transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol 2006 100: 462 8.
23. Khattar NH, Lele SM, Kaetzel CS. Down-regulation of the polymeric immunoglobulin receptor in non-small cell lung carcinoma: correlation with dysregulated expression of the transcription factors USF and AP2. J Biomed Sci 2005 12: 65 77.
24. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, et al. Loss of the AP-2α transcription factor is associated with the grade of human gliomas. Clin Cancer Res 2005 11: 267 72.
25. Hoei-Hansen CE, Nielsen JE, Almstrup K, Sonne SB, Graem N, Skakkebaek NE, et al. Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clin Cancer Res 2004 10: 8521 30.
26. Tellez C, McCarty M, Ruiz M, Bar-Eli M. Loss of activator protein-2α results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem 2003 278: 46632 42.
27. Fan WH, Karnovsky MJ. Increased MMP-2 expression in connective tissue growth factor over-expression vascular smooth muscle cells. J Biol Chem 2002 277: 9800 5.
28. Wajapeyee N, Somasundaram K. Cell cycle arrest and apoptosis induction by activator protein 2α (AP-2α) and the role of p53 and p21WAF1/CIP1 in AP-2α-mediated growth inhibition. J Biol Chem 2003 278: 52093 101.
29. Wajapeyee N, Raut CG, Somasundaram K. Activator protein 2α status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res 2005 65: 8628 34.
30. Wajapeyee N, Britto R, Ravishankar HM, Somasundaram K. Apoptosis induction by activator protein 2α involves transcriptional repression of Bcl-2. J Biol Chem 2006 281: 16 207 19.
31. Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 1999 6: 99 104.